BT44 is a novel, second-generation glial cell line-derived neurotropic factor mimetic with improved biological activity and is a lead compound for the treatment of neurodegenerative disorders. Like many other small molecules, it suffers from intrinsic poor aqueous solubility, posing significant hurdles at various levels for its preclinical development and clinical translation. Herein, we report a poly(2-oxazoline)s (POx)-based BT44 micellar nanoformulation with an ultrahigh drug-loading capacity of 47 wt %. The BT44 nanoformulation was comprehensively characterized by 1H NMR spectroscopy, differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), dynamic light scattering (DLS), and cryo-transmission/scanning electron microscopy (cryo-TEM/SEM). The DSC, XRD, and redispersion studies collectively confirmed that the BT44 formulation can be stored as a lyophilized powder and can be redispersed upon need. The DLS suggested that the redispersed formulation is suitable for parenteral administration (Dh ≈ 70 nm). The cryo-TEM measurements showed the presence of wormlike structures in both the plain polymer and the BT44 formulation. The BT44 formulation retained biological activity in immortalized cells and in cultured dopamine neurons. The micellar nanoformulation of BT44 exhibited improved absorption (after subcutaneous injection) and blood-brain barrier (BBB) penetration, and no acute toxic effects in mice were observed. In conclusion, herein, we have developed an ultrahigh BT44-loaded aqueous injectable nanoformulation, which can be used to pave the way for its preclinical and clinical development for the management of neurodegenerative disorders.
The main objective of this study is to formulate a library of difficult to solubilize drugs with four slightly different poly(2-oxazoline)s (POx) and poly(2-oxazine)s (POzi) based amphiphilic triblock copolymers and to elucidate whether the drug-polymer compatibility, as estimated by solubility parameters (SPs) might be used as tool to guide formulation development. The theoretical and experimental SPs of different homo-/triblock copolymers and 21 different hydrophobic drugs were calculated by two group contribution methods (i.e. Hoftyzer Van-Krevelen and Yamamoto molecular break method) and determined experimentally by solubility testing in list of selective solvents (for polymers only). The obtained SPs were further utilized to calculate the distance between polymers and drugs (Ra) in 3 dimensional Hansen space. Out of 21 structurally diverse drugs, the loading capacity (LC) was found to be higher than 40, 30, 20 and 10 wt.% for 4, 4, 3 and 5 drugs, respectively. In the remaining of 5 drugs the maximum achievable LC was found below 10 wt.%. The experimental results obtained by formulation development were not in accordance with the results predicted by Ra calculation. In contrast to several reports found in the literature, the determination of SPs and concurrent compatibility estimation appeared not to be a suitable tool to predict polymer-drug compatibility in the present system. As the predictive power of SPs is based on simple mathematical calculations, limiting the precise prediction of overall polarity, hydrogen bonding ability of molecules and interplay between the hydrophilic and hydrophobic domains resulting in differing deviations than predicted interactions thus might compromise the predictive power of HSPs.
BT44 is a novel, second generation glial cell line-derived neurotropic factor (GDNF) mimetic, with improved biological activity and a lead compound for the treatment of neurodegenerative disorders. Like many other small molecules, it suffers from intrinsic poor aqueous solubility, posing significant hurdles at various levels for its preclinical development and clinical translation. Herein, we report a poly(2-oxazoline)s (POx) based BT44 micellar nanoformulation with ultra-high drug loading capacity of 47 wt.%. The BT44 nanoformulation was comprehensively characterized by 1H-NMR spectroscopy, differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), dynamic light scattering (DLS) and cryo-transmission/scanning electron microscopy (cryo-TEM/SEM). The DSC, XRD and redispersion studies collectively confirmed that the BT44 formulation can be stored as a lyophilized powder and can be redispersed upon need. The DLS suggested that the redispersed formulation is suitable for parenteral administration (Dh ≈ 70 nm). The cryo-TEM measurements showed the presence of worm-like structures both in plain polymer and BT44 formulation. The BT44 formulation retained biological activity in immortalized cells and in cultured dopamine neurons. The micellar nanoformulation of BT44 exhibited improved absorption (after subcutaneous injection) and blood-brain barrier (BBB) penetration and no acute toxic effects in mice were observed. In conclusion, herein, we have developed an ultra-high BT44 loaded aqueous injectable nanoformulation, which can be used to pave way for its preclinical and clinical development for the management of neurodegenerative disorders.